Singapore grants provisional approval for the first bivalent COVID-19 booster vaccine

On Wednesday (September 14), the Health Sciences Authority (HSA) gave interim permission for the first bivalent COVID-19 booster vaccination to be used in the country.

The SARS-CoV-2 original strain and the Omicron BA.1 variant are the ones that are targeted by the two different components of the Spikevax Bivalent Original/Omicron COVID-19 injection that are manufactured by Moderna.

According to a statement made by HSA in a news release, it is an improved version of the Moderna COVID-19 vaccine that is only based on the primary SARS-CoV-2 strain.

Those patients aged 18 years and older who have previously been vaccinated against COVID-19 as part of the primary series are eligible to get it as a booster shot.

The provisional authorization was issued in accordance with the Pandemic Special Access Route in Singapore (PSAR).

According to statements made by Health Minister Ong Ye Kung in front of Parliament on Tuesday, the Ministry of Health has reached agreements with the pharmaceutical companies Pfizer-BioNTech and Moderna to deliver their new bivalent vaccinations into the country.

Keep Reading

Both the ancestral strain of COVID-19 and the Omicron variation, which includes the BA.4 and BA.5 strains, are targeted by the bivalent vaccinations.

The Moderna booster shot is a single dosage that consists of two components: 25 micrograms that target the original strain of SARS-CoV-2, and 25 micrograms that target the Omicron BA.1 variant.

In due time, the Expert Committee on COVID-19 Immunization and the Ministry of Health (MOH) will release official vaccination recommendations utilizing this booster, according to the HSA.

HSA stated that it had carefully examined the data from Moderna’s pre-clinical studies, clinical trials in human volunteers, manufacturing and quality controls, and reached the conclusion that the benefits of using the bivalent vaccine as a booster to protect against COVID-19 outweighed the risks of doing so. This was due to the fact that the virus is continuing to evolve.

In addition, the HSA stated that it engaged with members of its Medicines Advisory Committee and Panel of Infectious Diseases Experts before making its conclusion about the regulatory framework.

The regulatory body stated that its clinical analysis was based on an ongoing Phase 2/3 trial that was carried out by Moderna in people who were at least 18 years old.

Katherine S

1/4 German, 3/4 Malaysian. I write, follow and monitor closely political news happening in Malaysia, and other happening news in the ASEAN region. Newswriter for the best ASEAN news website - The Asian Affairs.

Recent Posts

V Surprises ARMY with Two Holiday Releases: A Festive Collab with Park Hyo-shin and “White Christmas” Cover

For K-pop fans, the Christmas season this year has become even more magical as several of their preferred stars reveal…

November 22, 2024

Celine Names TWS as Global Ambassadors Following Suzy Bae Announcement

After Suzy Bae's nomination as Celine's worldwide ambassador, the venerable French luxury fashion company has taken another bold step choosing…

November 22, 2024

Reddit Faces Widespread Outage, Users Turn to Workarounds Amid ‘Server Error’ Messages

Thousands of users of the well-known social network Reddit were left without access after a major outage of the website.…

November 22, 2024

Anne Hathaway Casted as ‘Verity’ in Colleen Hoover’s Book Adaptation

Anne Hathaway is slated to play the much expected film version of Colleen Hoover's best-selling book Verity in front of…

November 21, 2024

Gucci Set to Revolutionize Fashion Presentations with Unified Shows in 2025 under Sabato De Sarno’s Vision

Gucci is ready to change its presentation approach for 2025 in a radical action aimed to revolutionize the fashion industry.…

November 21, 2024

South Korea’s “Korea Discount”: Addressing the Governance Gap to Boost Market Value

As world investors wait for significant changes that might solve long-standing problems of governance and responsibility in South Korea's companies,…

November 21, 2024

This website uses cookies.

Read More